Hepatitis C

Dis Mon. 2014 May;60(5):201-12. doi: 10.1016/j.disamonth.2014.04.002.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Age Distribution
  • Anti-HIV Agents / therapeutic use*
  • Communicable Disease Control / organization & administration*
  • Disease Management
  • Female
  • Hepatitis C / diagnosis
  • Hepatitis C / drug therapy*
  • Hepatitis C / epidemiology*
  • Hepatitis C / transmission
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / transmission
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Incidence
  • Liver Cirrhosis / prevention & control*
  • Liver Cirrhosis / virology
  • Male
  • Middle Aged
  • Needs Assessment
  • Prisoners / statistics & numerical data
  • Prisons*
  • Ribavirin / adverse effects
  • Ribavirin / therapeutic use
  • Risk Assessment
  • Sex Distribution
  • Simeprevir
  • Sofosbuvir
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Telemedicine / statistics & numerical data
  • Treatment Outcome
  • United States
  • Uridine Monophosphate / adverse effects
  • Uridine Monophosphate / analogs & derivatives
  • Uridine Monophosphate / therapeutic use
  • Young Adult

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Sulfonamides
  • Ribavirin
  • Simeprevir
  • Uridine Monophosphate
  • Sofosbuvir